Obinutuzumab is effective for the treatment of rituximab-refractory PLA2R-associated membranous nephropathy
Obinutuzumab mainly induces short-term partial remissions in patients with rituximab-refractory primary membranous nephropathy, which may be related to the short follow-up period. However, this study demonstrates that obinutuzumab is an effective and safe treatment for rituximab-refractory PLA2R-associated membranous nephropathy.
Authors
- Wenyan Su (ORCID: https://orcid.org/0000-0001-7106-1271)
- Jing-Sheng Men
- Dan Liu (ORCID: https://orcid.org/0009-0004-6245-6027)
- Jianyi Li (ORCID: https://orcid.org/0009-0008-5859-4960)
- Yunzhao Wang (ORCID: https://orcid.org/0000-0002-7742-4536)
- Shuo Zhong
- Rong Wang (ORCID: https://orcid.org/0000-0003-2077-3249)
- Yao Zhang (ORCID: https://orcid.org/0000-0001-5659-562X)
- Jing Sun (ORCID: https://orcid.org/0000-0003-1183-1742)
- Haiping Wang (ORCID: https://orcid.org/0000-0002-1990-1517)
- Jie Gao
- Liang Xu
Institutions
- Shandong University (CN)
- Southeast University (BD)
- Shandong Provincial Hospital (CN)
- Jining First People's Hospital (CN)
- Shandong Provincial QianFoShan Hospital (CN)
- Shandong First Medical University (CN)
- Southeast University (CN)
- Nanjing Medical University (CN)
Publication Details
- Journal
- Clinical Kidney Journal
- Published
- 2025-05-01
- DOI
- https://doi.org/10.1093/ckj/sfaf026
- Citations
- 8
- Primary Topic
- Renal Diseases and Glomerulopathies
- Type
- article
- Field-Weighted Citation Impact
- 11.45
Funders
- Natural Science Foundation of Shandong Province
- Shandong First Medical University